Sickle cell disease causes accelerated kidney function decline, yet proven GFR-preserving therapies remain elusive. In this study of adults with sickle cell disease, RASi use was not associated with a significant difference in the rate of eGFR decline.
Fler avsnitt från "Kidney360"



Missa inte ett avsnitt av “Kidney360” och prenumerera på det i GetPodcast-appen.








